Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DOCA vs FLORINEF
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Desoxycorticosterone acetate (DOCA) is a mineralocorticoid hormone that binds to mineralocorticoid receptors in the distal renal tubules, promoting sodium reabsorption and potassium excretion, leading to increased extracellular fluid volume and blood pressure.
Fludrocortisone is a synthetic corticosteroid with predominantly mineralocorticoid activity, promoting sodium retention and potassium excretion in the distal renal tubules, thereby increasing extracellular fluid volume and blood pressure.
Adrenocortical insufficiency (Addison's disease),Salt-losing adrenogenital syndrome
Partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease,Salt-losing congenital adrenal hyperplasia,Postural hypotension (off-label)
Desoxycorticosterone acetate (DOCA) is administered intramuscularly at a dose of 2 to 5 mg daily or 10 mg every 12 hours initially, then reduced to 1 to 2 mg daily or every other day for maintenance. Alternatively, a pellet implant of 125 mg or 250 mg can be used for prolonged effect.
0.1 mg orally once daily, with range 0.1-0.2 mg/day. Dose may be divided twice daily if needed.
30-35 minutes; clinical context: short duration necessitates frequent dosing or continuous infusion for sustained effect.
Terminal elimination half-life: 3.5 hours; clinical effect half-life due to mineralocorticoid activity is longer (~12-24 hours), allowing once-daily dosing.
Primarily hepatic metabolism via reduction and conjugation; little is known about specific CYP enzymes.
Primarily hepatic via CYP3A4-mediated metabolism; also metabolized by 11β-hydroxysteroid dehydrogenase to inactive metabolites.
Primarily renal as metabolites; <5% unchanged. Biliary/fecal elimination is negligible (<2%).
Renal: ~80% as metabolites, ~20% unchanged; minimal biliary/fecal elimination.
~70% bound to plasma proteins (primarily albumin).
~90% bound to corticosteroid-binding globulin (CBG) and albumin.
Vd: 0.8-1.2 L/kg; indicates extensive tissue distribution with rapid redistribution from effect sites.
Vd: ~0.3 L/kg; distributes mainly into extracellular fluid and binds to renal mineralocorticoid receptors.
Oral: <5% due to extensive first-pass metabolism; IM/SC: 100%.
Oral: ~100% (well absorbed); no significant first-pass metabolism.
No specific dose adjustment is recommended for impaired renal function, but monitor for fluid retention and hypertension. Use with caution in patients with significant renal impairment.
No specific dose adjustment recommended based on GFR; use with caution in severe renal impairment due to sodium retention.
No specific dose adjustment for hepatic impairment, but use with caution due to potential electrolyte disturbances.
No specific adjustment for Child-Pugh; monitor for fluid overload in severe hepatic impairment.
Dose is not well established; use 0.1 to 0.2 mg/kg intramuscularly daily or adjust based on clinical response and serum electrolytes.
0.05-0.1 mg orally once daily; titrate based on response.
Start at the lower end of the dosing range (e.g., 1 to 2 mg IM daily) and monitor closely for fluid overload, hypertension, and electrolyte imbalances due to age-related decreased renal function and comorbidities.
Initiate at lower dose (0.05 mg daily) and titrate slowly; monitor for hypertension, hypokalemia, and fluid overload.
None
None
Fluid overload and edema,Hypokalemia,Hypertension,Cardiac hypertrophy and failure,Increased risk of infection due to immune suppression when used with glucocorticoids
May cause sodium retention and edema, especially in patients with cardiac disease,Monitor for hypokalemia and hyperglycemia,Increased risk of infections due to immunosuppression,May mask symptoms of infection,Do not use in patients with systemic fungal infections,Avoid abrupt discontinuation after prolonged therapy due to risk of adrenal insufficiency
Hypersensitivity to desoxycorticosterone or any component,Severe renal impairment,Hyperkalemia,Hypocalcemia,Congestive heart failure,Systemic fungal infections
Systemic fungal infections,Hypersensitivity to fludrocortisone or any component of the formulation,Concurrent live or attenuated virus vaccines (relative)
No specific food interactions are reported. However, maintain consistent sodium intake; do not restrict salt unless advised. Avoid potassium-rich foods if potassium levels are high. Alcohol may increase the risk of electrolyte disturbances.
Avoid excessive licorice (glycyrrhizin) which can enhance mineralocorticoid effects and worsen hypokalemia. Maintain a low-sodium diet to reduce fluid retention and hypertension. Increase potassium-rich foods if not contraindicated.
FDA Pregnancy Category C. First trimester: feminization of male fetuses, including hypospadias and clitoral hypertrophy, due to androgenic activity. Second and third trimesters: risk of virilization of female fetuses; no adequate human studies; avoid use unless potential benefit outweighs risk.
Fludrocortisone (Florinef) is a corticosteroid with mineralocorticoid activity. In animal studies, corticosteroids have been associated with cleft palate and other malformations. Human data are limited. First trimester exposure may slightly increase risk of oral clefts. Second and third trimester use may suppress fetal adrenal function, leading to neonatal adrenal insufficiency. Overall risk is low with short-term use, but chronic high doses should be avoided.
Excreted in breast milk in low amounts; M/P ratio not established. Potential for adverse effects in nursing infants (e.g., electrolyte disturbances, hypertension). Use caution; consider alternative therapies.
Fludrocortisone is excreted into breast milk in small amounts. The milk-to-plasma ratio is unknown. At typical doses, the amount ingested by the infant is likely to be low and not expected to cause adverse effects. However, monitor infant for signs of adrenal suppression. Use with caution, especially with high maternal doses.
No specific dose adjustments studied; monitor for increased volume of distribution and clearance; adjust based on clinical response and serum electrolyte levels. Use lowest effective dose.
Pharmacokinetic changes in pregnancy (increased volume of distribution, increased renal clearance) may reduce fludrocortisone levels, potentially requiring dose adjustment to maintain desired effect. Dose should be titrated based on clinical response (e.g., blood pressure, electrolyte levels). No specific dosing guidelines; individualize therapy.
DOCA (desoxycorticosterone acetate) is a mineralocorticoid used in adrenal insufficiency. Monitor serum potassium closely due to risk of hypokalemia from excessive mineralocorticoid activity. DOCA requires intramuscular injection; do not administer intravenously. Use in conjunction with glucocorticoids to mimic cortisol's permissive effects on catecholamines. Avoid in patients with hypertension, heart failure, or renal impairment due to sodium and water retention.
Monitor for signs of edema, hypertension, and hypokalemia. Use lowest effective dose. Caution in patients with heart failure, hypertension, or renal impairment. Do not abruptly discontinue; taper slowly. May interfere with cortisol assays.
This medication helps maintain salt and water balance in the body.,It is given as an injection into a muscle; do not inject into a vein.,Report signs of excessive fluid retention: swelling in legs, rapid weight gain, shortness of breath.,Monitor for muscle cramps or weakness which may indicate low potassium levels.,Avoid salt substitutes containing potassium without consulting your doctor.,Do not miss appointments for injections as consistent dosing is critical.,Carry medical identification indicating you take corticosteroid replacement therapy.
Take exactly as prescribed; do not stop suddenly without doctor's advice.,Weigh yourself daily and report rapid weight gain or swelling.,Monitor blood pressure regularly.,Eat a low-salt diet to help control fluid retention.,Report signs of high potassium (muscle weakness, irregular heartbeat) or low potassium (cramps, fatigue).,Carry medical ID indicating you take fludrocortisone.,Avoid excessive licorice intake (can worsen potassium loss).,May cause increased thirst and urination.
"Lidocaine, a sodium channel blocker and Class IB antiarrhythmic, inhibits hepatic CYP3A4, the primary enzyme responsible for the metabolism of quazepam, a benzodiazepine sedative-hypnotic. This inhibition reduces quazepam clearance, leading to elevated serum concentrations and enhanced sedative effects. Clinically, this may result in excessive sedation, respiratory depression, psychomotor impairment, and increased risk of falls, especially in elderly patients or those with hepatic impairment."
"Lidocaine and prilocaine are both amide-type local anesthetics that block voltage-gated sodium channels in neuronal membranes, inhibiting nerve impulse propagation. When used together, their systemic absorption can lead to additive cardiovascular and central nervous system toxicity, including arrhythmias, seizures, and methemoglobinemia, particularly with high doses or in patients with predisposing conditions."
"Lidocaine, a class Ib antiarrhythmic, inhibits CYP3A4, the primary enzyme responsible for the metabolism of ticagrelor, a P2Y12 platelet inhibitor. This inhibition can lead to increased plasma concentrations of ticagrelor, potentiating its antiplatelet effect and elevating the risk of major bleeding, such as gastrointestinal or intracranial hemorrhage. Conversely, reduced ticagrelor metabolism may also affect conversion to its active metabolite, though net effect still increases overall antiplatelet activity."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DOCA vs FLORINEF, answered by our medical review team.
DOCA is a Mineralocorticoid that works by Desoxycorticosterone acetate (DOCA) is a mineralocorticoid hormone that binds to mineralocorticoid receptors in the distal renal tubules, promoting sodium reabsorption and potassium excretion, leading to increased extracellular fluid volume and blood pressure.. FLORINEF is a Corticosteroid (Mineralocorticoid) that works by Fludrocortisone is a synthetic corticosteroid with predominantly mineralocorticoid activity, promoting sodium retention and potassium excretion in the distal renal tubules, thereby increasing extracellular fluid volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DOCA and FLORINEF depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DOCA is: Desoxycorticosterone acetate (DOCA) is administered intramuscularly at a dose of 2 to 5 mg daily or 10 mg every 12 hours initially, then reduced to 1 to 2 mg daily or every other day for maintenance. Alternatively, a pellet implant of 125 mg or 250 mg can be used for prolonged effect.. The standard adult dose of FLORINEF is: 0.1 mg orally once daily, with range 0.1-0.2 mg/day. Dose may be divided twice daily if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DOCA and FLORINEF in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DOCA is classified as Category C. FDA Pregnancy Category C. First trimester: feminization of male fetuses, including hypospadias and clitoral hypertrophy, due to androgenic activity. Second and third trimesters: ri. FLORINEF is classified as Category C. Fludrocortisone (Florinef) is a corticosteroid with mineralocorticoid activity. In animal studies, corticosteroids have been associated with cleft palate and other malformations. H. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.